Antiangiogenic therapy has become the most important treatment modality for patients with advanced hepatocellular carcinoma (HCC). In this study, the authors investigated levels of alpha-fetoprotein (AFP) as a potential biomarker for treatment efficacy of antiangiogenic therapy.
Department of Oncology, National Taiwan University Hospital, and Cancer Research Center, National Taiwan University School of Medicine, Taipei, Taiwan.
